N
NewLimit
Epigenetic reprogramming medicines to treat age-related disease
About NewLimit
NewLimit is a US biotechnology company developing medicines that aim to restore youthful function in old cells through epigenetic reprogramming. Co-founded in 2022 by Jacob Kimmel, Brian Armstrong and Blake Byers and based in the San Francisco Bay Area, the company works on the premise that cellular aging is reversible and that resetting the age of cells could both treat diseases of aging and help preserve health more broadly.
Epigenetic reprogramming changes the patterns of gene regulation in a cell without altering its DNA sequence. NewLimit searches for combinations of transcription factors and other interventions that shift old cells toward a younger state while keeping their identity, an approach that avoids turning cells back into stem cells. Its discovery platform combines single-cell genomics, high-throughput functional screening and machine learning to test large numbers of candidate interventions in human cells and predict which ones will rejuvenate them.
The company has applied this platform across programs in metabolic, vascular and immune health. Its most advanced work targets the liver, where a prototype medicine has been shown in preclinical studies to reverse the age of old human liver cells and help livers recover from injury and dietary stress. NewLimit plans to bring its first reprogramming medicine into human clinical trials.
NewLimit is a research and development stage company and does not yet sell products. It intends to develop and commercialize its own therapies and may partner with pharmaceutical companies on development.
Source: Dealroom company dataOpen roles
NewLimit in the South San Francisco ecosystem
The NewLimit office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A16 investors entered at this stage
Kleiner Perkins
Founders Fund
Dimension
Fred Ehrsam
Garry Tan
Eric Schmidt
Elad Gil
Joe Lonsdale
Patrick Collison
Nat Friedman
Daniel Gross
Valor Equity Partners
Joshua Kushner
John Collison
Human Capital
Khosla Ventures
Series B and later10 investors entered at this stage
Boost VC
Abstract Ventures
Eli Lilly
Brian Armstrong
Section 32
Duke Management Company
Greenoaks Capital Partners
Lilly Ventures
Quiet Capital
Thrive Capital
Source: Dealroom Talent Intelligence.
See NewLimit on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Vesalius Longevity Labs raises $6.5M, led by Equinox chairman Harvey Spevak
Forbes: NewLimit among the longevity-biotech bets drawing billionaire capital